Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures and by the associated comorbidities such as neurobiologic, cognitive, psychological, and social consequences of this condition. Up to 30 percent of patients with epilepsy is pharmacoresistant, and apart from those who are candidates for resective surgery, most will continue to have disabling seizures and a wide range of cognitive and psychiatric symptoms. Recurrent seizures and comorbidities in epilepsy impair patients’ health-related quality of life. Comorbidities and epilepsy have a bidirectional relationship, sharing common underlying pathogenesis. Until now, no conventional antiepileptic drugs commonly used is proven to provide the solid role in prevention of epileptogenesis or epilepsy related comorbidities. Therefore, it is critical to develop the novel drugs with the potential to benefit patients with pharmacoresistant.
The ketogenic diet has seen a revival in its clinical use in the past decade and demonstrates its effectiveness in ameliorating both seizures and cognitive concerns for the patients with pharmaocresistant epilepsy, which has motivated novel research studies into the mechanism of the ketogenic diet. Recent experimental studies also indicate that the ketogenic diet is a promising disease-modifying therapy for epilepsy. Therefore, the mechanisms underlying its anticonvulsive effects differ from those targeted by the current antiepileptic drugs. Despite the mechanisms underlying the ketogenic diet is still overall unclear, there is increasing evidence that the ketogenic diet likely involve a combination of multiple mechanisms to inhibit seizures, postpone disease progression as well as attenuate the epilepsy associated comorbidities.
In the Research Topic we wish to cover, but are not limited to, the following: i) epigenetic mechanism of the ketogenic diet; ii) ketogenic diet and AMPA receptors (glutamate receptors); iii) ketogenic diet and epileptogenesis; iv) ketogenic diet and adenosine system; v) ketogenic diet and comorbidities associated epilepsy; vi) ketogenic diet and sudden unexpected death in epilepsy (SUDEP)
Contributors are encouraged to submit original submissions in basic science and clinical investigations which have the potential to significantly advance the field. In addition to original research papers, we welcome the review articles covering novel insights into mechanisms mobilized by ketogenic diet therapies. All papers contributed to the field will be subjected to strict peer review.
Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures and by the associated comorbidities such as neurobiologic, cognitive, psychological, and social consequences of this condition. Up to 30 percent of patients with epilepsy is pharmacoresistant, and apart from those who are candidates for resective surgery, most will continue to have disabling seizures and a wide range of cognitive and psychiatric symptoms. Recurrent seizures and comorbidities in epilepsy impair patients’ health-related quality of life. Comorbidities and epilepsy have a bidirectional relationship, sharing common underlying pathogenesis. Until now, no conventional antiepileptic drugs commonly used is proven to provide the solid role in prevention of epileptogenesis or epilepsy related comorbidities. Therefore, it is critical to develop the novel drugs with the potential to benefit patients with pharmacoresistant.
The ketogenic diet has seen a revival in its clinical use in the past decade and demonstrates its effectiveness in ameliorating both seizures and cognitive concerns for the patients with pharmaocresistant epilepsy, which has motivated novel research studies into the mechanism of the ketogenic diet. Recent experimental studies also indicate that the ketogenic diet is a promising disease-modifying therapy for epilepsy. Therefore, the mechanisms underlying its anticonvulsive effects differ from those targeted by the current antiepileptic drugs. Despite the mechanisms underlying the ketogenic diet is still overall unclear, there is increasing evidence that the ketogenic diet likely involve a combination of multiple mechanisms to inhibit seizures, postpone disease progression as well as attenuate the epilepsy associated comorbidities.
In the Research Topic we wish to cover, but are not limited to, the following: i) epigenetic mechanism of the ketogenic diet; ii) ketogenic diet and AMPA receptors (glutamate receptors); iii) ketogenic diet and epileptogenesis; iv) ketogenic diet and adenosine system; v) ketogenic diet and comorbidities associated epilepsy; vi) ketogenic diet and sudden unexpected death in epilepsy (SUDEP)
Contributors are encouraged to submit original submissions in basic science and clinical investigations which have the potential to significantly advance the field. In addition to original research papers, we welcome the review articles covering novel insights into mechanisms mobilized by ketogenic diet therapies. All papers contributed to the field will be subjected to strict peer review.
